Market Intelligence, Preclinical Progress, and High-Purity Reagents for Transcription Factor Drug Development in Oncology, Metabolism, and Hemoglobinopathies.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ZBTB7A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Full-Length & Domains) | ZBTB7A (Pokemon/FBI-1) Full-Length, BTB/POZ Domain, and Zinc Finger Domain Recombinant Proteins. High purity (>95%), endotoxin <1 EU/µg, Sequence Verified. Ideal for SPR, ITC, AlphaScreen, and PROTAC ternary complex binding assays. | View ZBTB7A Products |
| Gene Delivery | ZBTB7A Premade ORF Lentivirus. Full-length coding sequence, high titer, sequence verified. Enables stable cell line generation, reporter assays, ChIP studies, and cellular target engagement (CETSA) experiments. | View ZBTB7A Products |
| Benchmark Ab | Anti-ZBTB7A Rabbit mAb. Recombinant positive control for WB, ChIP, IP, and IF validation. | View ZBTB7A Products |
| Validator | ZBTB7A siRNA Set (3 unique sequences). For knockdown verification, specificity controls, and HbF induction model validation. | View ZBTB7A Products |
| Related Target A | ZBTB7B (Th-POK). Paralog protein with high BTB-domain homology; critical for off-target selectivity screening. | View ZBTB7B Products |
| Related Target B | MYC. Convergent oncogenic network node; relevant for combination therapy screening and synthetic lethality studies. | View MYC Products |
| Related Target C | TP53 (p53). Tumor suppressor pathway; ZBTB7A negatively regulates p53 via ARF repression. Essential for pathway rescue and mechanism validation. | View TP53 Products |
| Related Target D | BCL6. Key interacting partner in lymphomagenesis; forms a PPI complex with ZBTB7A for transcriptional repression. | View BCL6 Products |
| Related Target E | BCL11A. Synergistic HbF silencing factor; dual-targeting strategies for sickle cell disease and beta-thalassemia. | View BCL11A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Paralog Selectivity (ZBTB7A vs ZBTB7B) | Purified ZBTB7A and ZBTB7B domain proteins (>95% purity) for orthogonal SPR/AlphaScreen counter-screens. |
| Intracellular Target Engagement | Lentivirus-based stable cell lines expressing ZBTB7A-ORF for cellular thermal shift (CETSA) and reporter assays. |
| PPI & Dimerization Inhibition (BTB domain) | Isolated BTB/POZ domain protein for homodimerization and heterodimerization (e.g., ZBTB7A-BCL6) assays (SPR/ITC/FP). |
| DNA-Binding Disruption (Zinc Finger) | Isolated Zinc Finger domain protein for fluorescence polarization (FP) or EMSA with labeled DNA probes. |
| Functional Knockdown Controls | Sequence-defined siRNA set to confirm on-target phenotype and exclude compound off-target effects. |
| PROTAC Ternary Complex Validation | High-purity full-length ZBTB7A and E3 ligase domains available for ternary complex formation assays (SPR/BLI). |
Live ZBTB7A R&D Tracker
Global Clinical Landscape & Future Outlook
The race for ZBTB7A (also known as Pokemon, FBI-1, or LRF) therapeutics is intensifying, moving from traditional kinase inhibitors toward transcription factor-targeted modalities including PROTACs, molecular glues, and genetic medicines. Initially characterized as an oncogenic driver in hepatocellular carcinoma, prostate cancer, and colorectal cancer via ARF/p53 pathway suppression, ZBTB7A has also emerged as a critical metabolic regulator controlling lipogenesis (ACLY, FASN) and a master repressor of fetal hemoglobin (HbF) in erythroid cells. Current R&D focuses on disrupting its BTB-domain mediated protein-protein interactions (e.g., homodimerization, ZBTB7A-BCL6) or its zinc finger DNA-binding capacity. The next wave of innovation is targeting PROTAC-mediated degradation for solid tumors and hematological malignancies, and transient pharmacological degradation or genetic modulation (siRNA/CRISPR) for hemoglobinopathies (sickle cell disease, beta-thalassemia) to induce HbF without permanent genetic alteration. As first-generation target validation matures, the field is pivoting toward paralog-selective inhibition and allosteric BTB-domain disruption to minimize toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule / PPI Inhibitor | Discovery-stage biotechs, academic consortia | Hepatocellular Carcinoma, Prostate Cancer, Colorectal Cancer, NAFLD | Protein stability & PPI disruption (Need purified BTB domain and full-length protein for SPR/AlphaScreen) |
| PROTAC / Degrader | Emerging targeted protein degradation platforms | Solid Tumors, Leukemia, Lymphoma | Target engagement & degradation validation (Need high-titer Lentivirus for stable lines and purified domains for ternary complex assays) |
| Molecular Glue | Early-stage pharma discovery units | Refractory Cancers, Metabolic Syndrome | Selectivity over paralog ZBTB7B and PPI stabilization (Need ZBTB7B ortholog and BTB domain proteins) |
| Genetic Medicines (siRNA/CRISPR) | Gene therapy biopharmas | Sickle Cell Disease, Beta-Thalassemia | Target engagement & knockdown validation (Need Sequence Verified Lentivirus/siRNA for HbF induction models) |
Molecular Differentiation & Assay Strategy (Internal Outlook)
Best-in-class drugs for ZBTB7A must differentiate across several dimensions:
- Affinity & Occupancy: Compounds must achieve nM-level affinity to outcompete high intracellular concentrations of DNA and protein complexes.
- Delivery & Exposure: Excellent cell membrane and nuclear membrane permeability is essential; Lentivirus-ORF stable cell lines enable CETSA and reporter assays.
- Mechanism of Action: Distinguish between BTB domain inhibition (disrupting repressor complex assembly) vs. zinc finger DNA-binding inhibition (directly blocking target gene regulation).
- Selectivity: Critical to establish >10-fold selectivity over close paralog ZBTB7B; include ZBTB7B in counter-screening panels.
TarMart provides all necessary tools for these differentiation steps: full-length and domain proteins, Lentivirus-ORF, siRNA controls, and paralog proteins for robust selectivity screening.